Sagimet Biosciences SGMT 深 滬
等待開盤 11-26 09:30:00 美东时间
6.98
+0.310
+4.65%
華盛通- 最 高7.00
- 今 開6.74
- 成交量 34.04万股
- 最 低 6.67
- 昨 收 6.67
- 總市值 2.27亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 1.05%
- 52周最低 1.73
- 委 比 86.27%
- 總股本 3252.16万
- 歷史最高 20.71
- 量 比 0.58
- 振 幅 4.95%
- 歷史最低 1.73
- 每 手 1
- 風險率 2.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences announced that its management will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, with a fireside chat at 12:55pm ET. A webcast of the event will be available on Sagimet’s website, with an archived replay for 90 days. Sagimet focuses on developing novel FASN inhibitors targeting metabolic and fibrotic pathways, with its lead product denifanstat showing positive results in clinical trials.
11-20 12:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Sagimet Biosciences shares are trading lower. The company reported Q3 financial results.
Sagimet Biosciences shares are trading lower. The company reported Q3 financial...
11-14 04:06
Sagimet Biosciences Q3 EPS $(0.40) Beats $(0.42) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.44 percent. This is a 11.11 percent increase over losses of $(0.45) per share
11-13 20:36
Sagimet Biosciences Presents Denifanstat Phase 2b Results Highlighting Advanced Fibrosis And Biomarker Improvements At AASLD 2025
A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathologyIn a
11-10 20:19
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Sagimet Biosciences announced that Denifanstat, an oral FASN inhibitor developed for treating moderate to severe acne, met all primary and secondary endpoints in a Phase 3 trial conducted by Ascletis in China. The trial, involving 480 patients, showed statistically significant improvements in acne severity and lesion reduction. Ascletis plans to submit an NDA to China's NMPA for Denifanstat shortly after completing pre-NDA consultations. Addition...
10-24 11:00
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Sagimet Biosciences, Inc. Class A (SGMT) Receives a New Rating from Clear Street
In a report released yesterday, Kaveri Pohlman from Clear Street initiated cove...
10-22 16:59
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Viking Therapeutics (NASDAQ:VKTX) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t...
10-09 23:33
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Sagimet Biosciences announced that analyses of the Phase 2b FASCINATE-2 study showing denifanstat's effectiveness in improving fibrosis in advanced fibrosis patients will be presented at the AASLD Liver Meeting 2025. Results demonstrate significant fibrosis improvement and biomarker benefits in patients, particularly those with advanced baseline fibrosis. Denifanstat, a fatty acid synthase inhibitor, is under development for metabolic dysfunction...
10-07 11:00
